FDA GLP-1 safety updates: how to read a changed warning
What FDA’s January 2026 GLP-1 warning change means, how the evidence developed, and how to check the right regulatory document.
Search explainers, questions, and medicine profiles.
Every published article, newest first. Reporting, explainers, and practical guides on weight and metabolic health.
What FDA’s January 2026 GLP-1 warning change means, how the evidence developed, and how to check the right regulatory document.
Body-composition numbers describe different things. Learn why lean mass is not the same as muscle and why function matters alongside measurements.
Plan recovery by looking at training, sleep, symptoms and daily demands, with flexible options for the days between harder sessions.
Plan exercise during GLP-1 treatment around appetite, symptoms and recovery, while keeping weight loss, lean mass and strength distinct.
When weight barely changes, assess fitness, function and well-being separately so the scale does not become the only judge of activity.
Notice the context around eating with curiosity, keep nourishment in view, and seek assessment when loss of control or distress becomes recurrent.
When treatment lowers appetite, make nourishment and symptom reporting part of the plan, with meals that fit your tolerance and medical needs.
Energy needs and weight responses change over time. Understand why a fixed deficit does not predict a straight line of weight loss.
What FDA approval does not cover for compounded GLP-1 products, with current shortage-policy context and questions about concentration and quality.